🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨 News 🚨 U.S. FDA has accepted the New Drug Application and granted Priority Review for ziftomenib in adult patients with relapsed/refractory NPM1-mutated #AML, based on results from the phase II KOMET-001 trial. Read more: loom.ly/rSqyl-I #AMLsm #leusm #MedNews

CONGRESS | #ASCO25 | POSTER Sankalp Arora Sankalp Arora, MD MD Anderson Cancer Center shares findings from a retrospective study comparing molecular and cytogenetic data between baseline and relapse, in adult patients with FLT3m AML who had relapsed following frontline FLT3i-based therapy (N

CONGRESS | #ASCO25 | POSTER Eunice Wang MD Roswell Park shares findings from a phase II study of olutasidenib in patients with R/R IDH1m AML who had received 1–2 (n = 93) or ≥3 (n = 54) prior treatment regimens. Patients with 1–2 prior regimens had a higher ORR and CR/CRh rate

CONGRESS | #ASCO25 | POSTER Justin Watts MD Sylvester Comprehensive Cancer Center shares findings from a matching-adjusted indirect comparison of olutasidenib vs ivosidenib, to estimate relative treatment effects in patients with IDH1m R/R AML (effective sample size = 73.03). A significantly longer

CONGRESS | #ASCO25 | POSTER Jennifer Croden MD Anderson Cancer Center shares insights from a retrospective analysis of outcomes with venetoclax (VEN)-based therapies in patients with therapy-related AML (N = 317). Median OS was lower with low-intensity therapy (LIT) than with LIT+VEN (5.7

CONGRESS | #ASCO25 | POSTER Mehmet Uyanik Mehmet S Uyanik, MD MD Anderson Cancer Center shares efficacy and safety results from a phase II trial (NCT04975919) of 10-day oral decitabine/cedazuridine (ASTX727) plus venetoclax in adult patients with R/R AML (N = 20). The ORR was 45%, and best response

CONGRESS | #ASCO25 | POSTER Harry Erba Duke Cancer presents the trial design of the ongoing phase III QuANTUM-Wild trial (NCT6578247) of quizartinib in combination with chemotherapy and as single-agent maintenance, in patients with newly diagnosed FLT3-ITD-negative AML. The

CONGRESS | #ASCO25 | PRESENTATION Eunice Wang MD Roswell Park presents results from the pivotal phase Ib/II KOMET-001 study (NCT04067336), of ziftomenib in patients with R/R NPM1m AML (N = 112). The phase II primary endpoint was met with 23% of phase II patients (n = 92) achieving

Stay up to date with the latest medical news in #AML by receiving trial data, therapy approvals, expert opinions, and more by signing up to our free newsletter: loom.ly/8kqU2Tw #amlsm #leusm #MedEd

CONGRESS | #ASCO25 | PRESENTATION Amer Zeidan MBBS,MHS ‏عامر زيدان Yale School of Medicine presents phase IIb data from the phase I/II ASCERTAIN-V trial of all-oral decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients with newly diagnosed AML ineligible for intensive induction chemotherapy (N =

CONGRESS | #ASCO25 | PRESENTATION Patricia Kropf Novant Health shares findings from a phase Ib/II study (NCT04964518) of the investigational oral BCL-2 inhibitor lisaftoclax (LISA) plus azacitidine (AZA) in patients with ND or R/R AML/MPAL, or high-risk MDS/CMML (N = 103). In the

CONGRESS | #ASCO25 | PRESENTATION Pierre Yves Dumas CHU de Bordeaux shares preliminary efficacy and dose selection results from the phase I/II EVICTION study of γ9δ2 T-cell activation with ICT01 combined with azacitidine (AZA) plus venetoclax (VEN), in older/unfit patients with ND

CONGRESS | #ASCO25 | PUBLICATION Vanessa Kennedy Vanessa Kennedy Stanford Medicine reports findings from an observational cohort study of real-world healthcare resource, treatment adherence, and dose modifications in patients with AML following allo-HCT with FLT3-TKI maintenance therapy

To conclude the @Know_AML HCP–patient webinar, titled ‘Mutation testing in AML: What you need to know’, the faculty shared the key takeaways and addressed questions from the audience. Watch here: loom.ly/yY_OLqg #KnowAML #AMLsm #leusm

🚨 #EHA2025 is nearly here! The list of top abstracts selected by the AML Hub Steering Committee for the European Hematology Association 2025 Congress is now available to view👉 loom.ly/rNFKzN4 #AMLsm #leusm #MedicalCongress

What barriers do you encounter when conducting multiple MRD tests during treatment? A. Limited access to MRD testing (e.g., lack of availability internally at the institution therefore samples have to be sent to external labs) B. Cost and reimbursement challenges (e.g.,

🚨Catch up on the latest developments in acute myeloid leukemia from #ASCO25 with our social media coverage. loom.ly/abwU0TM #AMLsm #leusm #MedicalCongress

🎧 New podcast! Listen to Charlie Craddock CBE, Queen Elizabeth Hospital Birmingham UK, discussing mutations in AML, during an HCP–patient webinar hosted by @Know_AML. Listen: loom.ly/4R6dJ4M Watch: loom.ly/Mu4X9OQ #KnowAML #AMLsm #leusm